PAPIX

Sitagliptin Phosphate is an oral antidiabetic agent belonging to the DPP-4 (Dipeptidyl Peptidase-4) inhibitor class. It is widely used in the treatment of type 2 diabetes mellitus to improve glycemic control, particularly in patients who are not adequately managed by diet and exercise alone. Sitagliptin works by increasing incretin levels, which help regulate insulin secretion and reduce glucagon levels.

As an API, Sitagliptin Phosphate is manufactured under cGMP-certified facilities, ensuring high purity, excellent stability, and compliance with international regulatory standards (USP/EP). It is commonly used in both monotherapy and fixed-dose combination products with other antidiabetic agents like Metformin.